Pharma Deals Review, Vol 2008, No 94 (2008)

Font Size:  Small  Medium  Large

Regulus' microRNA Proves Attractive to GSK

Sally Mardikian PhD

Abstract


GSK is another big pharma looking at the potential of RNAi technologies in this deal with Regulus.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.